Adenosine Receptor A3 - Pipeline Review, H1 2020
Adenosine Receptor A3 - Pipeline Review, H1 2020
SUMMARY
According to the recently published report 'Adenosine Receptor A3 - Pipeline Review, H1 2020'; Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.
The report 'Adenosine Receptor A3 - Pipeline Review, H1 2020' outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1, 6, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Immunology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Male Health, Oncology, Ophthalmology, Infectious Disease, Musculoskeletal Disorders, Respiratory and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Glaucoma, Inflammation, Kidney Fibrosis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chemotherapy Induced Pain, Chronic Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammatory Pain, Liver Cancer, Male Sexual Dysfunction, Melanoma, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis and Ulcerative Colitis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Adenosine Receptor A3 - Pipeline Review, H1 2020'; Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.
The report 'Adenosine Receptor A3 - Pipeline Review, H1 2020' outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1, 6, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Immunology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Male Health, Oncology, Ophthalmology, Infectious Disease, Musculoskeletal Disorders, Respiratory and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Glaucoma, Inflammation, Kidney Fibrosis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chemotherapy Induced Pain, Chronic Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammatory Pain, Liver Cancer, Male Sexual Dysfunction, Melanoma, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis and Ulcerative Colitis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
Adenosine Receptor A3 (ADORA3) - Drug Profiles
BIO-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namodenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Autoimmune Disorders, Inflammation, Liver Cancer and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Apr 14, 2020: Can Fite to conduct investor call to review positive phase II NASH data
Apr 13, 2020: Can Fite received approval for covid-19 clinical trial in Israel, patient enrollment and dosing to commence immediately
Apr 07, 2020: Can-Fite reports positive top line results from its phase II NASH study with Namodenoson
Mar 30, 2020: Can-Fite implements interim analysis for its phase III psoriasis trial with data expected Q4 2020
Mar 23, 2020: Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel
Mar 18, 2020: Can-Fite to participate in Digital Bio-Europe Spring Partnering Conference; looks to partner on co-development of Piclidenoson for coronavirus treatment
Mar 16, 2020: Can-Fite: Progress in compassionate use program treating advanced liver cancer patients with Namodenoson
Mar 11, 2020: Can-Fite: New pre-clinical studies demonstrate inhibition of fat cell expansion by Cannabis derived CBD
Mar 05, 2020: Can-Fite updates on clinical milestone for its Phase III rheumatoid arthritis study with Piclidenoson; drugs combating rheumatoid arthritis are currently introduced for the treatment of the Coronavirus
Mar 03, 2020: Can-Fite is filing drug safety update report showing positive safety result phase II study of Namodenoson
Mar 03, 2020: Can-Fite is filing drug safety update report showing positive safety result phase III study of piclidenoson
Feb 27, 2020: Pre-clinical studies demonstrate CBD’s robust anti-cancer effect against liver cancer; Can-Fite and Univo Pharmaceuticals expand Collaboration Agreement
Feb 24, 2020: Can Fite files patent for Namodenoson to overcome drug resistance to checkpoint inhibitors for oncology indications
Feb 18, 2020: Can-Fite granted patent allowance for its NASH drug Namodenoson in South Korea; results of its NASH Phase II study are expected this quarter
Feb 13, 2020: Can-Fite submits Liver Cancer phase III protocol and registration plan to EMA for Namodenoson
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
Adenosine Receptor A3 (ADORA3) - Drug Profiles
BIO-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namodenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Autoimmune Disorders, Inflammation, Liver Cancer and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Apr 14, 2020: Can Fite to conduct investor call to review positive phase II NASH data
Apr 13, 2020: Can Fite received approval for covid-19 clinical trial in Israel, patient enrollment and dosing to commence immediately
Apr 07, 2020: Can-Fite reports positive top line results from its phase II NASH study with Namodenoson
Mar 30, 2020: Can-Fite implements interim analysis for its phase III psoriasis trial with data expected Q4 2020
Mar 23, 2020: Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel
Mar 18, 2020: Can-Fite to participate in Digital Bio-Europe Spring Partnering Conference; looks to partner on co-development of Piclidenoson for coronavirus treatment
Mar 16, 2020: Can-Fite: Progress in compassionate use program treating advanced liver cancer patients with Namodenoson
Mar 11, 2020: Can-Fite: New pre-clinical studies demonstrate inhibition of fat cell expansion by Cannabis derived CBD
Mar 05, 2020: Can-Fite updates on clinical milestone for its Phase III rheumatoid arthritis study with Piclidenoson; drugs combating rheumatoid arthritis are currently introduced for the treatment of the Coronavirus
Mar 03, 2020: Can-Fite is filing drug safety update report showing positive safety result phase II study of Namodenoson
Mar 03, 2020: Can-Fite is filing drug safety update report showing positive safety result phase III study of piclidenoson
Feb 27, 2020: Pre-clinical studies demonstrate CBD’s robust anti-cancer effect against liver cancer; Can-Fite and Univo Pharmaceuticals expand Collaboration Agreement
Feb 24, 2020: Can Fite files patent for Namodenoson to overcome drug resistance to checkpoint inhibitors for oncology indications
Feb 18, 2020: Can-Fite granted patent allowance for its NASH drug Namodenoson in South Korea; results of its NASH Phase II study are expected this quarter
Feb 13, 2020: Can-Fite submits Liver Cancer phase III protocol and registration plan to EMA for Namodenoson
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by BioIntervene Inc, H1 2020
Pipeline by Can-Fite BioPharma Ltd, H1 2020
Pipeline by Future Medicine Co Ltd, H1 2020
Pipeline by Palo BioFarma SL, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by BioIntervene Inc, H1 2020
Pipeline by Can-Fite BioPharma Ltd, H1 2020
Pipeline by Future Medicine Co Ltd, H1 2020
Pipeline by Palo BioFarma SL, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
